| abstract |
“COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION ''.nPharmaceutical compounds, methods and compositions are provided to reduce the amount or activity of FXI RNA in a cell or subject and, in certain cases, to reduce the amount of FXI protein in a cell or subject. Such compounds, methods and pharmaceutical compositions are useful to prevent, treat or ameliorate at least one symptom of a thromboembolic condition without a significant increase in the risk of bleeding. Such thromboembolic conditions include deep venous thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis or another procoagulant condition. Such symptoms include decreased blood flow through an affected vessel, tissue death and death. |